About this trial

Arteriovenous fistula or graft are the ideal hemodialysis access. Nonetheless the most common access type used for Continuous Renal Replacement Therapy (CRRT) is either a temporary or permanent hemodialysis catheter. Recommendations for the use of catheters to deliver CRRT in end stage kidney disease (ESKD) patients are lacking on data and subjective to anecdotal experiences and expert consensus. The repetitive placement of catheters in ESKD patients have shown to increase the chances of central vascular stenosis which is one of the main risk factors that lead to access failure. Also, the repetitive use of dialysis catheters increases the risk for catheter associated infections. Dedicated studies demonstrating the safety and feasibility of using arteriovenous access (AVA) for CRRT are scarce. No screening criteria or algorithm exists to determine the adequate patient and clinical scenario to use AVA for CRRT.

Goals of the study:

1. To develop a standard operating procedure for the use of AVA in CRRT. 2. Evaluate the safety and efficacy of using AVA for CRRT.

Eligibility criteria

Qualifiers

Age 18 years or older

Diagnosis of End-Stage Kidney Disease (ESKD) receiving maintenance chronic hemodialysis

Admission to the Intensive Care Unit (ICU)

Presence of a functioning arteriovenous fistula (AVF) or arteriovenous graft (AVG)

Disqualifiers

Age under 18 years

Arteriovenous access thrombectomy within 30 days prior to study enrollment

Documented prolonged bleeding from arteriovenous access within 30 days prior to study enrollment

Current dialysis via temporary or tunneled hemodialysis catheter

Trial design

Treatments tested in this trial

  • Cannulation of permanent dialysis access, for the purpose of delivering continuous renal replacement therapy.

Treatment groups

50 Participants
are divided into 1 treatment group

Locations

1
East Carolina University Medical Center27834, GreenvilleNorth Carolina, United States

Sponsors and collaborators

East Carolina University

Lead sponsor